Palash Sharma

ORCID: 0000-0003-3016-7541
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Diet and metabolism studies
  • Neurological Complications and Syndromes
  • Dementia and Cognitive Impairment Research
  • Mitochondrial Function and Pathology
  • Colorectal Cancer Screening and Detection
  • Diabetes Treatment and Management
  • Statistical Methods in Clinical Trials
  • Statistical Methods and Inference
  • Pharmacology and Obesity Treatment
  • Diabetes Management and Research
  • Radiomics and Machine Learning in Medical Imaging
  • Alzheimer's disease research and treatments
  • Statistical Methods and Bayesian Inference
  • Health, Environment, Cognitive Aging
  • Neurological and metabolic disorders
  • Epilepsy research and treatment
  • Dialysis and Renal Disease Management
  • Phytoestrogen effects and research
  • Medical Education and Admissions
  • Colorectal Cancer Surgical Treatments
  • Pancreatic function and diabetes
  • Metabolomics and Mass Spectrometry Studies
  • Biosimilars and Bioanalytical Methods
  • Probabilistic and Robust Engineering Design
  • Health Systems, Economic Evaluations, Quality of Life

Eli Lilly (United States)
2023-2025

University of Kansas Medical Center
2009-2024

REVA University
2024

Veterans Health Administration
2022

Birla Institute of Technology and Science - Hyderabad Campus
2021

Birla Institute of Technology and Science, Pilani
2021

Tufts Medical Center
2020

Regional Medical Center
2009

Rationale & ObjectiveKidney disease negatively affects cognition. We assessed the effect of kidney transplantation (KT) on different cognitive domains.Study DesignProspective cohort study.Setting ParticipantsWe examined pre- to post-KT cognition in patients waitlisted for KT at an academic center.PredictorsTransplant status. measured function pre-KT (n=101), three months (n=78), and 1-year (n=83).OutcomesOur primary outcome was change post-KT. used standard neuropsychological tests assess...

10.1053/j.ajkd.2023.12.022 article EN cc-by American Journal of Kidney Diseases 2024-02-28

Treating obesity may be a pathway to prevent and control hypertension. In the SURMOUNT-1 trial in people with or overweight weight-related complications, 72-week tirzepatide treatment led clinically meaningful body weight blood pressure reduction. Post hoc analyses were conducted further explore effects of on pattern reduction whether consistent across various subgroups.

10.1136/heartjnl-2024-324170 article EN cc-by-nc Heart 2024-07-31

In this study, the thermal conductivity of titania (TiO2)–water nanofluid was predicted using five separate machine learning algorithms with their unique hyperparameters and logical functions. A detailed comparative study on TiO2–water dataset performed artificial neural network (ANN), gradient boosting regression (GBR), support vector (SVR), decision tree (DTR), random forest (RFR) algorithms. complete data intelligence analysis 228 collected points different shape size conducted. The...

10.1016/j.csite.2021.101658 article EN cc-by-nc-nd Case Studies in Thermal Engineering 2021-11-26

Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist approved in the US for treating type 2 diabetes (T2D) and obesity, has demonstrated significant improvements glycated hemoglobin A1c (HbA1c) clinically meaningful weight loss SURPASS-1 to -5 clinical trials. This post hoc analysis examined safety efficacy results tirzepatide older participants with T2D who do not have obesity. A was conducted on subgroup of aged ≥ 65 years body...

10.1007/s13300-025-01711-0 article EN cc-by-nc Diabetes Therapy 2025-02-28

Abstract Aims This participant‐level exploratory analysis assessed the continuous time spent in glycaemic control and/or with sustained weight reductions tirzepatide treatment participants type 2 diabetes (T2D) from SURPASS programme. Materials and Methods Participants ( N = 6246) 1–5 were randomized to once weekly (5, 10 or 15 mg) comparator (once placebo, semaglutide 1 mg, insulin degludec glargine). Continuous HbA1c < 7.0% (53 mmol/mol), ≤6.5% (48 mmol/mol) ≥5% body reduction combined...

10.1111/dom.16337 article EN Diabetes Obesity and Metabolism 2025-03-13

OBJECTIVE To evaluate late (week 40 or 42; hereafter, week 40/42) metabolic outcomes by early glycemic response (<20% ≥20% fasting serum glucose [FSG] reduction at 4) weight (<5% ≥5% 8), respectively, in tirzepatide-treated participants with type 2 diabetes the SURPASS trials. RESEARCH DESIGN AND METHODS This post hoc analysis used pooled data across Baseline characteristics, change from baseline to 40/42 for efficacy parameters, and gastrointestinal (GI) adverse events (AEs)...

10.2337/dc24-2790 article EN Diabetes Care 2025-03-18

<p dir="ltr">Objective To evaluate late (Week 40/42) metabolic outcomes by early glycemic response (<20% or ≥20% fasting serum glucose [FSG] reduction at Week 4) weight (<5% ≥5% 8), respectively, in tirzepatide-treated participants with type 2 diabetes the SURPASS trials. Research Design and Methods This post hoc analysis used pooled data across Baseline characteristics, change from baseline to 40/42 for efficacy parameters, gastrointestinal adverse events (GI AEs) were described...

10.2337/figshare.28500443 preprint EN cc-by-nc-sa 2025-03-18

<p dir="ltr">Objective To evaluate late (Week 40/42) metabolic outcomes by early glycemic response (<20% or ≥20% fasting serum glucose [FSG] reduction at Week 4) weight (<5% ≥5% 8), respectively, in tirzepatide-treated participants with type 2 diabetes the SURPASS trials. Research Design and Methods This post hoc analysis used pooled data across Baseline characteristics, change from baseline to 40/42 for efficacy parameters, gastrointestinal adverse events (GI AEs) were described...

10.2337/figshare.28500443.v1 preprint EN cc-by-nc-sa 2025-03-18

Inherited mitochondrial DNA (mtDNA) variants may influence Alzheimer's disease (AD) risk.We sequenced mtDNA from 146 AD and 265 cognitively normal (CN) subjects the University of Kansas Center (KUADC) assigned haplogroups. We further considered 244 242 CN Neuroimaging Initiative (ADNI) with equivalent data.Without applying multiple comparisons corrections, KUADC haplogroup J frequencies were 16.4% versus 7.6% (P = .007), K 4.8% 10.2% .063). ADNI 10.7% 7.0% .20), 4.9% 8.7% .11). For combined...

10.1002/alz.12119 article EN Alzheimer s & Dementia 2020-06-16

Significance Statement Kidney disease is accompanied by structural and physiologic brain abnormalities increased risk of dementia stroke. Because RRT with dialysis does not normalize these abnormalities, the authors evaluated possible benefit kidney transplantation. Using magnetic resonance imaging methods to measure before after transplantation, they demonstrated that this intervention normalizes cerebral blood flow, neurochemical concentrations, white matter integrity. They also found...

10.1681/asn.2020050584 article EN Journal of the American Society of Nephrology 2020-10-16

This prospective study aimed to describe the clinical course in terms of glycemic outcomes, body weight, and adverse events during first 12 weeks following a switch from glucagon-like peptide-1 receptor agonists (GLP-1 RAs) directly tirzepatide 5 mg.

10.1016/j.eprac.2024.05.005 article EN cc-by-nc-nd Endocrine Practice 2024-05-08

End-stage kidney disease has been associated with cognitive impairment and brain atrophy. It remains unclear if mild to moderate dysfunction is atrophy, especially in older adults. We used cross-sectional data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), an NIH-funded multicenter longitudinal cohort study, better understand association between estimated glomerular filtration rate (eGFR) volumes. included all ADNI participants both baseline serum creatinine values MRI volume...

10.1159/000521892 article EN American Journal of Nephrology 2022-01-01

Alzheimer's Disease (ad) associates with insulin resistance and low aerobic capacity, suggestive of impaired skeletal muscle mitochondrial function. However, this has not been directly measured in AD. This study ( n = 50) compared respiratory function gene expression profiling cognitively healthy older adults (CH; 24) to 26 individuals the earliest phase ad-related cognitive decline, mild impairment (MCI; 11) or MCI taking ad medication donepezil (MCI + med; 15). Mitochondrial kinetics were...

10.1093/function/zqab045 article EN cc-by Function 2021-01-01

Recent developments in literature on sample size calculations for time-to-event outcomes involve assumption of Weibull distributed times. These methods require a point estimate the shape parameter obtained from historical studies. However, very limited guidance exists published to assess how reliable this is when it results study.We conduct simulations accurate and estimated median survival time and/or corresponding interquartile range. Accuracy assessed using criteria average relative bias,...

10.1016/j.conctc.2020.100548 article EN cc-by-nc-nd Contemporary Clinical Trials Communications 2020-02-26

Being hearing or speech differently-abled may hinder the communication of an individual, thus goal proposed approach is to reduce gap between a and normal person. We aim develop hand Glove that can convert sign language speech, as well display text on App. In addition, App will also be able do reverse into language. To create complete translator translate vice versa. The aimed solve problems faced by impaired people enable better for them. It implemented using Arduino, Convolutional Neural...

10.1063/5.0184057 article EN AIP conference proceedings 2024-01-01

This study aimed to describe the clinical course in terms of changes glycemic outcomes and body weight adverse event occurrence 12 weeks following a switch from GLP-1 RA tirzepatide 5 mg, with 2.5-mg initiation dose omitted. In this open-label study, participants were ≥18 years old type 2 diabetes (T2D), HbA1c ≥6.5% ≤9.0%, mass index (BMI) ≥25 kg/m2, on stable treatment RAs for ≥3 months (liraglutide 1.2 or 1.8 mg once daily, dulaglutide 0.75, 1.5, 3, 4.5 weekly [QW], injectable semaglutide...

10.1016/j.eprac.2024.03.159 article EN other-oa Endocrine Practice 2024-05-01

ABSTRACT Stochastic curtailment tests for Phase II two‐arm trials with time‐to‐event end points are traditionally performed using the log‐rank test. Recent advances in designing have utilized Weibull distribution a known shape parameter estimated from historical studies. As sample size calculations depend on value of this parameter, these methods either cannot be used or likely underperform/overperform when natural variation around point estimate is ignored. We demonstrate that magnitude...

10.1002/pst.2429 article EN Pharmaceutical Statistics 2024-08-18

This study examines how AirBNB utilizes user pathway information to enhance customer satisfaction. AirBNB, a quickly growing online platform for housing, prioritizes satisfaction by constantly enhancing its interface and features. method heavily depends on analyzing data. By paths, gains insights into behavior preferences. is used improve search recommendations, make booking smoother, identify areas needing enhancement. In conclusion, aims provide smooth satisfying experience through their...

10.21844/mijia.20.1.5 article EN Management Insight - The Journal of Incisive Analysers 2024-12-18

The University of Kansas Alzheimer's Disease Center (KU ADC) maintains several large databases to track participant recruitment, enrollment, and capture various research-related activities. It is challenging manage coordinate all the One crucial activities involves generating a consensus diagnosis communicating with participants their primary care providers.To effectively cohort, KU ADC utilizes combination open-source electronic data (EDC) (i.e. REDCap), along other homegrown management...

10.1093/jamiaopen/ooab060 article EN cc-by JAMIA Open 2021-07-01

ABSTRACTAs part of the drug development process, interim analysis is frequently used to design efficient phase II clinical trials. A stochastic curtailment framework often deployed wherein a decision continue or curtail trial taken at each look based on likelihood observing positive negative treatment effect if were its anticipated end. Thus, can take place due evidence early efficacy futility. Traditionally, in case time-to-event endpoints, monitoring conducted two-arm using log-rank test,...

10.1080/10543406.2023.2244056 article EN Journal of Biopharmaceutical Statistics 2023-08-14

Abstract Background Mitochondrial genetics are important in the etiology of Alzheimer’s disease (AD). Based on polymorphisms mitochondrial DNA (mtDNA) population can be classified into subgroups called haplogroups. Previous studies have explored association haplogroups and genetic variants APOE ε4 with AD but results inconsistent. Also, patients mild cognitive impairment (MCI) at baseline often progress differently over several years follow up. Method We carried out a cross‐sectional study...

10.1002/alz.042362 article EN Alzheimer s & Dementia 2020-12-01

Abstract Background Chronic kidney disease (CKD) is associated with abnormalities in cerebral blood flow (CBF), neurochemical concentrations and white matter integrity, each of which are adverse clinical consequences the non-CKD population, may explain high prevalence dementia stroke end stage (ESKD). Since cognition improves after transplantation (KT), we examined these brain pre-to post-KT to identify potential reversibility ESKD-associated abnormalities. Methods We measured effects KT on...

10.1101/2020.05.04.20091199 preprint EN cc-by-nc-nd medRxiv (Cold Spring Harbor Laboratory) 2020-05-08
Coming Soon ...